Elicio Therapeutics, Inc. (ELTX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US28657F1030
Elicio Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -37.71 m USD |
| EBIT | -38.44 m USD |
| Net income | -39.57 m USD |
| Diluted EPS – continuing operations | -2.58 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
More stocks
- Connect Biopharma Holdings Ltd (CNTB)
- Histeel (071090.KS)
- TSI Co. Ltd. (277880.KQ)
- Wiable Corp (065530.KQ)
- Pan Global Resources Inc (PGZ.V)
- XBP Global Holdings, Inc. (XBP)
- Dogwood Therapeutics, Inc. (DWTX)
- Lithium Chile Inc (LITH.V)
- Biomea Fusion, Inc. (BMEA)
- Joosung Corperation (109070.KS)
- Jericho Oil Corp (JEV.V)
- Ene Technology Inc (6243.TW)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.